Company / SG&A Expense
X4 Pharmaceuticals, Inc SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$35.5M
FY2025
5-year range
$8.7M / $35.5M
FY2021-FY2025
Trend
+31.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 5 consecutive years, from $7M in FY2018 to $36M in FY2025.
Based on SEC 10-K filings.
$36M in FY2025 with a 5-year CAGR of +32.4%.
Increased from $21M to $36M over the past 3 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +19.2%
- 5-Year CAGR
- +32.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- X4 Pharmaceuticals, Inc's sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +32.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 31.4% year-over-year.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $35.5M | +31.4% |
| FY2024 | $27.0M | +29.0% |
| FY2022 | $20.9M | +18.7% |
| FY2021 | $17.6M | +101.9% |
| FY2020 | $8.7M | +34.1% |
| FY2018 | $6.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026